Success Story: NIW Approval Secured for Biomedical Postdoctoral Researcher Improving Treatment Outcomes in Cancer and Infectious Diseases
Client’s Testimonial:
“Thank you so much for all your help during this process. It was great working with you.”
On January 22nd, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Research Scientist in the field of Biomedicine (Approval Notice).
General Field: Biomedicine
Position at the Time of Case Filing: Postdoc
Country of Origin: Iran
State of Residence at the Time of Filing: Ohio
Approval Notice Date: January 22nd, 2025
Processing Time: 7 months, 9 days (Premium Processing Requested)
Case Summary:
A biomedical postdoctoral researcher focusing on therapeutic innovation recently secured approval for an EB-2 National Interest Waiver (NIW), recognizing the national significance of her ongoing efforts to address drug resistance in cancer and infectious diseases. Her research centers on developing combination drug regimens designed to improve treatment efficacy while reducing adverse effects, an endeavor that aligns directly with pressing U.S. public health priorities.
Her academic foundation as an M.D. and her practical research background have enabled her to make meaningful contributions to biomedical science. Her work explores how novel therapeutic strategies can overcome treatment limitations in challenging diseases, ultimately aiming to improve patient outcomes in areas where current options remain insufficient.
She has established a growing scholarly record, with five peer-reviewed publications and one preprint. These works had accrued 87 independent citations at the time of filing—a figure that continued to rise during adjudication—demonstrating sustained field impact. Colleagues in the field have noted the meaningful impact of her research, describing its importance in addressing some of medicine’s most challenging problems. As one expert explained:
“Through her multifaceted approach to research, [Client] has made significant strides in addressing pressing healthcare challenges, such as drug resistance in treating cancer and infectious diseases, positioning herself as a prominent figure in the field of biomedicine.”
Her proposed endeavor is not only scientifically compelling but also nationally important. By advancing therapeutic strategies that can improve treatment response and reduce resistance across major disease categories, her work contributes to efforts that could reduce mortality, lower healthcare burdens, and support long-term public health resilience.
Her successful NIW approval reflects both the value of her contributions and the strength of the documentary evidence prepared and presented by North America Immigration Law Group (NAILG) on her behalf.
Through her continued research, she is positioned to make sustained contributions that advance therapeutic development and improve the nation’s ability to address complex medical challenges, and NAILG is proud to have supported her in achieving this important milestone.